HOME
  • About Shionogi
    • About Shionogi
      • Message from Top Management
      • Brand Statement
      • Shionogi's Strength
      • Management Philosophy
      • Company Profile
      • Management Strategy
      • Operations
      • Compliance
      • Group Companies
      • Corporate Governance
      • Policies
      • History
  • Sustainability
    • Sustainability
      • Material Issues (Materiality)
      • Address the problem of antimicrobial resistance (AMR)
      • Environment
      • Society
      • Governance
      • Access to Healthcare
      • Stakeholder Engagement
      • Annual Report / Integrated Report / Environment Report
      • Data
      • External Evaluation
      • About United Nations Global Compact
      • Information related to infectious diseases
  • Innovation
    • Innovation
      • R&D
      • IP Strategy
      • Partnering
      • Pipeline
      • Wastewater-based Epidemiology Surveillance Service
  • News
  • Investors
    • Investors
      • Top Message
      • Latest IR Information
      • IR Library
      • Management Policy
      • Shareholder Information
      • Individual Investors
      • Sustainability
      • Financial Highlights
      • IR Calendar
  • Contact Us
  • Careers
English
Worldwide
Commitment to Fight COVID-19

Commitment to Fight COVID-19

As of May 30, 2022

[Wastewater-based Epidemiology Surveillance Service]

[Wastewater-based Epidemiology Surveillance Service]

By measuring the traces of the virus in wastewater, it is possible to assess, in an unbiased manner, the prevalence of SARS-CoV-2 infections in a community, including asymptomatic individuals who are not tested.

our medium-term business plan

[Mid-term Business plan]

STS2030

~Shionogi Transformation Strategy 2030~

Outline / CEO interview movie

Drive Innovation

[Innovation]

Drive Innovation

Create innovations beyond the borders of medical / Pharmaceutical fields, unbound from existing concepts, showing every consideration for social issues

Sustainability

[Sustainability]

Grow sustainably as a drug discovery based pharmaceutical company contributing to a more vigorous society through improved healthcare

News

Jan.24, 2023 Release
Shionogi to Announce Personnel Reassignment
Jan.17, 2023 Release
Initiation of a Phase1/2/3 Clinical Trial (Part 2) and Phase 3 Additional Dose Clinical Trial in Japanese Pediatric Subjects of the COVID-19 Recombinant Protein-based Vaccine, S-268019
Jan.04, 2023 Release
New Drug Application of Ensitrelvir Fumaric Acid, a Therapeutic Drug for COVID-19 Accepted for Review in South Korea
Dec.29, 2022 Release
Notice Regarding a License Agreement for the Promotion of Ensitrelvir Fumaric Acid, a Therapeutic Drug for COVID-19, in China
Dec.23, 2022 Release
Notice Regarding a License Agreement for Import and Distribution of Ensitrelvir Fumaric Acid, a Therapeutic Drug for COVID-19, in China
News

Commitment to Fight COVID-19

Shionogi's effort to fight with COVID-19

Beware of Solicitations, “Phishing” e-mails, and SNS that Fraudulently Use the Name of SHIONOGI

Site Search

Brand Statement

Building innovation platforms to shape the future of healthcare.

SHIONOGI is transforming our business model from a "drug-discovery-oriented pharmaceutical company" to a "healthcare provider" to pursue the health that people truly wish for and deliver new value to society.

more

About Shionogi

We are fully committed to achieving the goals of STS2030 and strive to realizing "SHIONOGI Group heritage" globally.

Sustainability

Shionogi's susutainability programs which toward to become a company that will be needed by stakeholders now and in the future.

Innovation

Shionogi's Innovation always comes from the passion to provide new value which meet the needs of society and customers, in the healthcare field.

Investors

Based on disclosure policy, Shionogi disclose information fairly, timely, appropriately and continuously to all stakeholders.

  • About Shionogi
  • Sustainability
  • Innovation
  • News
  • Investors
  • Terms of Service
  • Sitemap
  • Personal Information
Copyright (C) Shionogi & Co., Ltd. All Rights reserved.